Leading U.S. cancer research institute successfully defends antibody patent in Europe

Client(s) Leading U.S. cancer research institute

Jones Day successfully represented major U.S. cancer research institute in opposition proceedings before the European Patent Office. The patent covers monoclonal antibodies for use in the treatment of B cell malignancies and other autoimmune disorders. The notice of opposition was filed by a strawman, not revealing the true identity of the company driving the opposition. The Opposition Division's first instance decision to maintain the patent as granted became final on appeal. The patent is licensed to a major biotechnology company.